Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 1998

View Archived Issues

Zaleplon shows advantage over zolpidem for sleep disorders in phase III

U.S. patent licensed to Avax Technologies issued for anticancer compounds

Company Profile: Pacific Pharmaceuticals

Corixa to acquire GenQuest

Phase II retreatment trial with Bexxar commences

Oxidized phenolic compounds with an unexpected mechanism of action

TX-525, a potent synthetic progestin with low androgenic potential

European trial of Bextra initiated

5alpha-Reductase inhibitor from Merck with potential in treating acne

Rhone-Poulenc Rorer seeks FDA approval for CFC-free Intal Inhaler

Parke-Davis discusses development of potent, irreversible EGF receptor TK inhibitors

University of British Columbia awarded grant to study vanadium compounds

Regulatory approval sought for lamivudine in U.S. for treatment of hepatitis B

Inhibitors of Ras function patented by Schering-Plough

Early studies with JE-2147 yield promising results

Boehringer Ingelheim presents new leukotriene antagonists

Factor Xa inhibitors developed by Boehringer Mannheim researchers

Astra devotes significant resources to development of immunomodulatory peptides

Termination of Gilead-Glaxo Wellcome code blocker collaboration

Hydroxyurea in combination regimens enhances anti-HIV activity

First launch for Bayer's miglitol

U.K. introduction for Viracept

Fujisawa scientists identify potent, nonpeptide bradykinin antagonist

No dose-limiting toxicity found yet for AN-9 in phase I

DPPE proves highly effective and well tolerated in metastatic breast cancer patients

Agouron in-licenses S-1153; phase I results presented at AIDS conference

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...